Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, Hariprasad Vankayalapati, Alexis Weston, Trason Thode, Kapil N Bhalla, Serina NG, Ryan Rodrigues Del Villar, Kevin Drenner, Mohan R Kaadige, Stephen K Horrigan, Surinder K Batra, Ravi Salgia, Sunil Sharma
Results announced from dose escalation study of tegavivint in desmoid tumors.
Iterion Therapeutics announces presentation of three posters involving research into tegavivint at the AACR 2022 Annual Meeting
Iterion initiates Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.
Children’s Oncology Group Pediatric Early Phase Clinical Trials Network, a National Cancer Institute-supported clinical trials group, sponsors first clinical study for tegavivint in the pediatric population
Iterion Therapeutics announces phase 1 clinical trial.
Iterion Therapeutics hires Jean Chang as Chief Operating Officer.
Iterion Therapeutics confirms safety of tegavivint following completion of enrollment in phase 1/2a expansion study.
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings.
